Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Cytosorbents Corp.

CTSO

CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.

Last trade $5.19
Day change +$0.34 (+7.01%)
Day range $4.50 – $5.36
Volume 21,737
Market cap $15M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$15.28M
Price / earnings
—
Price / book
-20.35×
Price / sales
0.41×
EV / sales
0.76×
EV / EBITDA
-2.62×

Profitability

Earnings per share
-$5.78
Return on assets
-47.98%
Return on equity
2,425.17%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-22.96×
Current ratio
0.66×
Quick ratio
0.5×
Cash ratio
0.18×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.3M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CTSO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$9.63M$8.86M$9.23M$9.49M$9.62M$8.73M$9.15M$8.61M
Cost of revenue$2.58M$2.73M$2.43M$2.82M$2.8M$2.52M$2.9M$3.36M
Gross profit$7.05M$6.13M$6.8M$6.67M$6.81M$6.21M$6.26M$5.26M
Selling, general and administrative$7.96M$8.15M$9.44M$8.61M$9.17M$8.43M$7.64M$8.26M
Research and development$1.45M$1.03M$1.24M$918K$1.26M$1.66M$2.02M$1.83M
Total operating expenses$9.69M$9.17M$11.19M$9.53M$10.43M$10.1M$9.65M$10.09M
Operating income-$2.64M-$3.04M-$4.39M-$2.86M-$3.62M-$3.89M-$3.4M-$4.83M
Interest expense-$868K-$857K$0$0-$616K-$605K$0$0
Income before taxes-$4.42M-$5.13M-$5.5M-$3.57M$1.95M-$1.48M-$9.26M-$2.77M
Income taxes$0$0$0-$401K$0$0-$1.69M$0
Net income-$4.42M-$5.13M-$5.5M-$3.17M$1.95M-$1.48M-$7.57M-$2.77M
Net income attributable to common shareholders-$4.42M-$5.13M-$5.5M-$3.17M$1.95M-$1.48M-$7.57M-$2.77M
EBITDA-$2.02M-$2.69M-$3.52M-$2.5M-$3.21M-$3.52M-$3.01M-$4.45M
Basic earnings per share-$1.40-$1.60-$1.75-$1.00$0.60-$0.40-$3.01-$1.00
Diluted earnings per share-$1.40-$1.60-$1.89-$1.00$0.60-$0.40-$3.01-$1.00

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Benzinga

CytoSorbents Provides Regulatory Update for DrugSorb-ATR

CytoSorbents Corporation received a denial letter from the FDA regarding its De Novo Request for DrugSorb-ATR, a device designed to reduce bleeding in CABG patients on the antiplatelet drug Brilinta. The company plans to continue working with the FDA to resolve the remaining issues and obtain regulatory approval.

GlobeNewswire Inc.

CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue

CytoSorbents Corporation reported strong preliminary Q4 2024 financial results, with product revenue growth estimated at 22-25% year-over-year and gross margin improving to around 70%. The company also provided updates on its regulatory progress for DrugSorb-ATR, an investigational device to reduce perioperative bleeding in CABG surgery patients.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Sep 8, 20261-for-20reverse split
Dec 5, 20141-for-25reverse split
Jun 28, 20061-for-5.8reverse split